Baker McKenzie advised Gimv NV on the deal. WorxInvest completed the acquisition of a 27.81% stake in Gimv NV from the Flemish Participation Company VPM in a transaction...
WorxInvest’s Acquisition of a Stake in Gimv NV
Minoryx Therapeutics and Neuraxpharm Group’s Development of a New CNS Therapy in Europe
Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...